Cisplatin as first-line therapy for metastatic breast cancer

G. W. Sledge, P. J. Loehrer, B. J. Roth, L. H. Einhorn

Research output: Contribution to journalArticle

180 Citations (Scopus)

Abstract

Cisplatin has had only minimal activity when used as second- and third-line chemotherapy for metastatic breast cancer (MBC). There have been no phase II studies in the United States evaluating cisplatin in patients with MBC with no prior chemotherapy. We therefore treated 20 consecutive patients with cisplatin 30 mg/m2/d for four days every 3 weeks for a maximum of six courses. We obtained partial responses in nine of 19 evaluable patients (47%), with responses in liver, lung, and soft tissue indicator lesions. Our data suggest that cisplatin has substantial single-agent activity as front-line therapy in MBC, and should be considered for inclusion in first-line combination chemotherapy regimens.

Original languageEnglish (US)
Pages (from-to)1811-1814
Number of pages4
JournalJournal of Clinical Oncology
Volume6
Issue number12
DOIs
StatePublished - Jan 1 1988

Fingerprint

Cisplatin
Breast Neoplasms
Drug Therapy
Therapeutics
Combination Drug Therapy
Lung
Liver

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cisplatin as first-line therapy for metastatic breast cancer. / Sledge, G. W.; Loehrer, P. J.; Roth, B. J.; Einhorn, L. H.

In: Journal of Clinical Oncology, Vol. 6, No. 12, 01.01.1988, p. 1811-1814.

Research output: Contribution to journalArticle

@article{222d801b6acd401e813c32e7a8facac7,
title = "Cisplatin as first-line therapy for metastatic breast cancer",
abstract = "Cisplatin has had only minimal activity when used as second- and third-line chemotherapy for metastatic breast cancer (MBC). There have been no phase II studies in the United States evaluating cisplatin in patients with MBC with no prior chemotherapy. We therefore treated 20 consecutive patients with cisplatin 30 mg/m2/d for four days every 3 weeks for a maximum of six courses. We obtained partial responses in nine of 19 evaluable patients (47{\%}), with responses in liver, lung, and soft tissue indicator lesions. Our data suggest that cisplatin has substantial single-agent activity as front-line therapy in MBC, and should be considered for inclusion in first-line combination chemotherapy regimens.",
author = "Sledge, {G. W.} and Loehrer, {P. J.} and Roth, {B. J.} and Einhorn, {L. H.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1200/JCO.1988.6.12.1811",
language = "English (US)",
volume = "6",
pages = "1811--1814",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Cisplatin as first-line therapy for metastatic breast cancer

AU - Sledge, G. W.

AU - Loehrer, P. J.

AU - Roth, B. J.

AU - Einhorn, L. H.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Cisplatin has had only minimal activity when used as second- and third-line chemotherapy for metastatic breast cancer (MBC). There have been no phase II studies in the United States evaluating cisplatin in patients with MBC with no prior chemotherapy. We therefore treated 20 consecutive patients with cisplatin 30 mg/m2/d for four days every 3 weeks for a maximum of six courses. We obtained partial responses in nine of 19 evaluable patients (47%), with responses in liver, lung, and soft tissue indicator lesions. Our data suggest that cisplatin has substantial single-agent activity as front-line therapy in MBC, and should be considered for inclusion in first-line combination chemotherapy regimens.

AB - Cisplatin has had only minimal activity when used as second- and third-line chemotherapy for metastatic breast cancer (MBC). There have been no phase II studies in the United States evaluating cisplatin in patients with MBC with no prior chemotherapy. We therefore treated 20 consecutive patients with cisplatin 30 mg/m2/d for four days every 3 weeks for a maximum of six courses. We obtained partial responses in nine of 19 evaluable patients (47%), with responses in liver, lung, and soft tissue indicator lesions. Our data suggest that cisplatin has substantial single-agent activity as front-line therapy in MBC, and should be considered for inclusion in first-line combination chemotherapy regimens.

UR - http://www.scopus.com/inward/record.url?scp=0024271629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024271629&partnerID=8YFLogxK

U2 - 10.1200/JCO.1988.6.12.1811

DO - 10.1200/JCO.1988.6.12.1811

M3 - Article

C2 - 3199166

AN - SCOPUS:0024271629

VL - 6

SP - 1811

EP - 1814

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -